JP2013520990A5 - - Google Patents

Download PDF

Info

Publication number
JP2013520990A5
JP2013520990A5 JP2012556068A JP2012556068A JP2013520990A5 JP 2013520990 A5 JP2013520990 A5 JP 2013520990A5 JP 2012556068 A JP2012556068 A JP 2012556068A JP 2012556068 A JP2012556068 A JP 2012556068A JP 2013520990 A5 JP2013520990 A5 JP 2013520990A5
Authority
JP
Japan
Prior art keywords
antibody
antibody fragment
mab
seq
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012556068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520990A (ja
JP5911813B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/000415 external-priority patent/WO2011109108A1/en
Publication of JP2013520990A publication Critical patent/JP2013520990A/ja
Publication of JP2013520990A5 publication Critical patent/JP2013520990A5/ja
Application granted granted Critical
Publication of JP5911813B2 publication Critical patent/JP5911813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012556068A 2010-03-04 2011-03-04 Ｃｄ２０に対するモノクローナル抗体 Expired - Fee Related JP5911813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31044010P 2010-03-04 2010-03-04
US61/310,440 2010-03-04
PCT/US2011/000415 WO2011109108A1 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to cd20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016068492A Division JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2013520990A JP2013520990A (ja) 2013-06-10
JP2013520990A5 true JP2013520990A5 (enExample) 2014-04-17
JP5911813B2 JP5911813B2 (ja) 2016-04-27

Family

ID=44542488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012556068A Expired - Fee Related JP5911813B2 (ja) 2010-03-04 2011-03-04 Ｃｄ２０に対するモノクローナル抗体
JP2016068492A Pending JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016068492A Pending JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Country Status (7)

Country Link
US (2) US9616120B2 (enExample)
EP (1) EP2542262A4 (enExample)
JP (2) JP5911813B2 (enExample)
AU (2) AU2011221553B2 (enExample)
BR (1) BR112012022338A2 (enExample)
CA (1) CA2791560A1 (enExample)
WO (1) WO2011109108A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010110838A2 (en) 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
EP2496604B1 (en) * 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
SG10201500957QA (en) * 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
ES3014160T3 (en) 2015-12-18 2025-04-21 Intervet Int Bv Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3014461C (en) * 2016-02-18 2023-02-28 Elanco Us Inc. Chimeric canine anti-cd20 antibody
US11648265B2 (en) 2016-08-10 2023-05-16 Aurelius Biotherapeutics, Llc Cell therapy compositions and methods of use thereof
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB202217993D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
WO2024158001A1 (ja) 2023-01-25 2024-08-02 日本全薬工業株式会社 イヌのｂ細胞リンパ腫の治療方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU640397B2 (en) * 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
PT100379B (pt) * 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
EP0803834A3 (en) * 1996-04-25 2000-06-28 Olympus Optical Co., Ltd. Memory card installing device
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
ES2288886T3 (es) 1999-12-30 2008-02-01 Dana-Farber Cancer Institute, Inc. Proteoliposomas que contienen una proteina integral de membrana que tiene uno o mas dominios transmembrana.
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
JP4723810B2 (ja) * 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド抗体
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CA2469833C (en) * 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1476120B1 (en) 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
EP1694706B1 (en) * 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
JPWO2005075640A1 (ja) 2004-02-10 2008-01-10 学校法人日本大学 イヌｃｄ２０遺伝子
EP1751187A2 (en) * 2004-05-28 2007-02-14 Idexx Laboratories, Inc. Canine cd20 compositions
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
CN101238150A (zh) 2005-05-24 2008-08-06 阿维斯塔金格兰技术有限公司 用于治疗慢性淋巴细胞性白血病的抗cd52单克隆抗体的重组生产方法
DK2573114T3 (en) * 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
EA015992B1 (ru) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US20080112961A1 (en) 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
EP2331579B1 (en) 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
WO2010110838A2 (en) 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES

Similar Documents

Publication Publication Date Title
JP2013520999A5 (enExample)
CY1123791T1 (el) Μονοκλωνικο αντισωμα ιντερλευκινης-31
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
NZ588713A (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
BR112012022338A2 (pt) anticorpos monoclonais direcionados a cd20
BR112012007365A2 (pt) proteínas de ligação à il-1
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
WO2011050106A3 (en) Anti-cd3 antibody dosing in autoimmune disease
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
BRPI0916945A2 (pt) métodos para tratar uma doença auto-imune ou distúrbio inflamatório em um indivíduo humano, para tratar esclerose múltipla em um indivíduo, e para identificar anticorpos, anticorpo humano, humanizado ou quimérico isolado ou um fragmento de ligação de antígeno do mesmo, e, proteína de ligação isolada.
BR112013028523A8 (pt) Uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
RU2016100892A (ru) Антитела против tweakr и их применение
JP2014503189A5 (enExample)
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
MX2015012540A (es) Ratón de cadena ligera común.
AR077594A1 (es) Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
JP2014061000A5 (enExample)
MX353278B (es) Raton con cadena ligera comun.
MX379533B (es) Ratones de cadena ligera universal humanizados.
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.